NABOTA® is a high-purity Botulinum Toxin Type A formulation developed by Daewoong Pharmaceuticals. FDA-approved and backed by multiple clinical trials, it delivers reliable, temporary smoothing of moderate to severe dynamic wrinkles.
Composition
- Clostridium botulinum toxin type A: 200 U
- Human serum albumin: 0.5 mg
- Sodium chloride: 0.9 mg
Appearance & Reconstitution
Supplied as a white-to-light-yellow lyophilisate in a clear vial. Reconstitute with sterile, preservative-free 0.9 % saline to achieve 4 U/0.1 mL (200 U/5 mL). Gently swirl; avoid agitation—label with date/time and use within 24 hours.
Mechanism of Action
NABOTA® inhibits acetylcholine release at neuromuscular junctions, producing localized muscle relaxation that softens expression lines and relieves hyperactive muscle conditions.
Indications
Aesthetic
- Temporary improvement of moderate to severe glabellar lines
- Forehead lines
- Crow’s feet
- Periorbital and perioral wrinkles
Therapeutic
- Chronic migraine prevention
- Neurogenic detrusor overactivity (urinary incontinence)
- Axillary hyperhidrosis
Administration
Inject intramuscularly using a 30–33 G needle. Tailor dose and injection sites to individual anatomy and treatment goals. Typical interval between treatments is 3–6 months.
Storage & Shelf Life
Store unopened vials at 2–8 °C; do not freeze. Maintain aseptic handling of the reconstituted product. Shelf life: 36 months from manufacture.
Safety & Precautions
Administer only by licensed professionals. Inspect the solution for particulate matter and discoloration before use. Contraindicated in patients with known hypersensitivity to any component. Common adverse events include injection-site discomfort, localized weakness, and transient ptosis. Serious systemic effects are rare but warrant prompt medical attention.
Disclaimer:
Bruno Dermal Fillerth products are strictly intended for use by licensed medical and aesthetic professionals. Not suitable for self-administration or use by untrained individuals.
